Dosing Strategies for Lithium Monotherapy in Children and Adolescents with Bipolar I Disorder
Publication Type
Journal Article
Year of Publication
2011
Authors
Findling, R; Kafantaris, V; Pavuluri, M; McNamara, N; McClellan, J; Frazier, J; Sikich, L; Kowatch, R; Lingler, J; Faber, J; Rowles, B; Clemons, T; Taylor-Zapata, P
Secondary
J Child Adolesc Psychopharmacol
Volume
21
Start Page
195
Pagination
195-205
Date Published
06/2011
Keywords
Adolescent; Antimanic Agents; Bipolar Disorder; Body Weight; Child; Dose-Response Relationship; Drug; Evidence-Based Medicine; Female; Humans; Lithium Carbonate; Male; Severity of Illness Index; Treatment Outcome
Abstract
Objective: The primary goal of this exploratory study was to obtain data that could lead to evidence-based dosing strategies for lithium in children and adolescents suffering from bipolar I disorder. Methods: Outpatients aged 7-17 years meeting Diagnostic and Statistical Manual of Mental Disorders, 4th edition, diagnostic criteria for bipolar I disorder (manic or mixed) were eligible for 8 weeks of open label treatment with lithium in one of three dosing arms. In Arm I, participants began treatment at a dose of 300 mg of lithium twice daily. The starting dose of lithium in Arms II and III was 300 mg thrice daily. Patients in Arms I and II could have their dose increased by 300 mg/day, depending on clinical response, at weekly visits. Patients in Arm III also had mid-week telephone interviews after which they could also have their dose of lithium increased by 300 mg per day. Youths weighing <30 kg were automatically assigned to Arm I, whereas youths weighing >/=30 kg were randomly assigned to Arm I, II, or III. Randomization was balanced by age (7-11 years, 12-17 years) and sex in approximately equal numbers. A priori response criteria were defined as a Clinical Global Impressions-Improvement scale score of =2 and a 50% decrease from baseline on the Young Mania Rating Scale. Results: Of the 61 youths [32 males (52.5%)] who received open-label lithium, 60 youths completed at least 1 week of treatment and returned for a postbaseline assessment. Most patients had a >/=50% improvement in Young Mania Rating Scale score, and more than half of the patients (58%) achieved response. Overall, lithium was well tolerated. All three treatment arms had similar effectiveness, side effect profiles, and tolerability of lithium. Conclusions: On the basis of these results, a dosing strategy in which pediatric patients begin lithium at a dose of 300 mg thrice daily (with an additional 300 mg increase during the first week), followed by 300 mg weekly increases until a priori stopping criteria are met, will be used in an upcoming randomized, placebo-controlled trial.
- Log in to post comments
- Google Scholar
- BibTeX